Ipca Laboratories receives USFDA’s EIR for Tarapur API facility

09 Feb 2026 Evaluate

Ipca Laboratories has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility situated at Tarapur. The EIR classifies the manufacturing facility as ‘Voluntary Action Indicated’ (VAI) and that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP). 

The USFDA had conducted an inspection at said facility from December 1, 2025 to December 5, 2025. 

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.

Ipca Laboratories Share Price

1488.55 13.15 (0.89%)
13-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1698.10
Dr. Reddys Lab 1267.60
Cipla 1330.85
Zydus Lifesciences 904.85
Lupin 2199.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×